【摘要】 目的:评价雷帕霉素(RPM)口服液联合环孢素(CsA)预防肾移植术后早期急性排斥反应的疗效。方法:首次肾移植患者20例,随机分成RPM试验组和硫唑嘌呤(Aza)对照组,每组各10例,分别接受以CsA和类固醇激素为基础的免疫抑制治疗方案6mo,比较2组人/肾存活率、急性排斥反应发生、不良事件发生等指标的差异。结果:17例完成治疗者人/肾均存活;仅Aza组1例发生2次急性排斥反应;2组各发生2例严重不良事件。结论:RPM联合CsA可有效预防移植肾急性排斥反应,并维持肾功能于良好水平,但是也可能增强CsA的肝毒性。更多还原

【Abstract】 OBJECTIVES:To evaluate the efficacy of rapamycin(RPM)oral liquid plus cyclosporine(CsA)on the prevenˉtion of early acute rejection after renal allograft.METHODS:20patients undergoing primary renal allografting were randomly divided into RPM trial group and Azathioprine(Aza)control group,10cases in each group,who were respectively assigned to receive CsA and adrenocortial hormones-based immunosuppression for6months,indexes including survival rates of recipients/kidneys,incidences of acute rejection and adverse reactions between2groups were compared.RESULTS:For the17patients who had finished6-month treatment,the survival rates(recipients/kidneys)were100%.Only2episodes of acute rejection occurred in one case in Aza group.Both groups had2cases of severe adverse episodes.CONCLUSIONS:The combined therapy pf RPM plus CsA is effective in the prevention of acute renal allograft rejection,and it can maintain renal function at a good level.Nevertheless,it may increase the hepatotoxicity of CsA.更多还原